A Review of Emerging ARNI Data in HFrEF

Published: 27 November 2019

  • Views:

    Views Icon 756

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.

Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.

Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.

This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
 

EBAC Accreditation

This video series was funded by an unrestricted educational grant from Novartis.

Educational Objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019
  • Understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases)
  • Interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data
  • Apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized patients.

More from this programme

Part 1

ARIADNE in Review

In this video, Prof Uwe Zeymer (Klinikum Ludwigshafen, Ludwigshafen, DE) discusses the ARIADNE trial - understanding the current utilization of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) therapy in HFrEF.
1 session
ARIADNE in Review Watch now

Part 2

Commentary on ARIADNE

In this video Prof Scott Solomon (Harvard Medical School, MA, US) and Prof Andrew Coats (University of Warwick, UK) discuss the ARIADNE trial.
1 session
Commentary on ARIADNE Watch now

Part 3

PROVE-HF in Review

In this video, Prof James Januzzi (Harvard Medical School, MA, US) presents a comprehensive review of PROVE-HF - Interpreting potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data.
1 session
PROVE-HF in Review Watch now

Part 4

EVALUATE in Review

In this video, Prof Akshay Desai (Harvard Medical School, MA, US) presents a comprehensive review of EVALUATE-HF.
1 session
EVALUATE in Review Watch now

Part 5

Commentary on PROVE-HF and EVALUATE

In this video Prof Scott Solomon (Harvard Medical School, MA, US) and Prof Andrew Coats (University of Warwick, UK) discuss the PROVE-HF and the EVALUATE-HF trials.
1 session
Commentary on PROVE-HF and EVALUATE Watch now

Part 6

TRANSITION-CHF in Review

In this video, Prof Rolf Wachter (Leipzig University Hospital, Leipzig, DE) presents a comprehensive review of TRANSITION-CHF.
1 session
TRANSITION-CHF in Review Watch now

Part 7

PIONEER in Review

In this video, Prof David A Morrow, Professor of Medicine and Cardiology from the Harvard Medical School, Boston, MA, US, discusses the emerging data on utilising Angiotensin Receptor-Neprilysin Inhibitor (ARNI) therapy in complex patients.
1 session
PIONEER in Review Watch now

Part 8

Commentary on TRANSITION-CHF and PIONEER

In this video Prof Scott Solomon (Harvard Medical School, MA, US) and Prof Andrew Coats (University of Warwick, UK) discuss the TRANSITION-CHF and the PIONEER trials.
1 session
Commentary on TRANSITION-CHF and PIONEER Watch now

Faculty Biographies

James L Januzzi

James L Januzzi

Director of the Cardiac Intensive Care Unit

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

Dr Januzzi was the top-ranked graduate in his class at New York Medical College. He completed an internship and residency at Brigham and Women’s Hospital prior to performing a clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, where he also completed a fellowship in cardiac ultrasound. 

He speaks widely on the topic of biomarker testing in heart disease and treatment of heart failure.  He has served as the Cardiology Consultant to the Boston Red Sox since 2005.

View full profile